Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help?

Mohamad Nasir Shafiee, Gulafshana Khan, Rina Ariffin, Jafaru Abu, Caroline Chapman, Suha Deen, David Nunns, David A. Barrett, Claire Seedhouse, William Atiomo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic.

Original languageEnglish
Pages (from-to)248-253
Number of pages6
JournalGynecologic Oncology
Volume132
Issue number1
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Polycystic Ovary Syndrome
Metformin
Endometrial Neoplasms
Endometrial Hyperplasia
Hyperinsulinism
Type 2 Diabetes Mellitus
Insulin Resistance
Obesity
Insulin
Research

Keywords

  • Endometrial cancer
  • Endometrial hyperplasia
  • Metformin
  • PCOS

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women : Could metformin help? / Shafiee, Mohamad Nasir; Khan, Gulafshana; Ariffin, Rina; Abu, Jafaru; Chapman, Caroline; Deen, Suha; Nunns, David; Barrett, David A.; Seedhouse, Claire; Atiomo, William.

In: Gynecologic Oncology, Vol. 132, No. 1, 01.2014, p. 248-253.

Research output: Contribution to journalArticle

Shafiee, MN, Khan, G, Ariffin, R, Abu, J, Chapman, C, Deen, S, Nunns, D, Barrett, DA, Seedhouse, C & Atiomo, W 2014, 'Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help?', Gynecologic Oncology, vol. 132, no. 1, pp. 248-253. https://doi.org/10.1016/j.ygyno.2013.10.028
Shafiee, Mohamad Nasir ; Khan, Gulafshana ; Ariffin, Rina ; Abu, Jafaru ; Chapman, Caroline ; Deen, Suha ; Nunns, David ; Barrett, David A. ; Seedhouse, Claire ; Atiomo, William. / Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women : Could metformin help?. In: Gynecologic Oncology. 2014 ; Vol. 132, No. 1. pp. 248-253.
@article{a47afd565d4b428b9bdbe98d84b84cef,
title = "Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: Could metformin help?",
abstract = "Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic.",
keywords = "Endometrial cancer, Endometrial hyperplasia, Metformin, PCOS",
author = "Shafiee, {Mohamad Nasir} and Gulafshana Khan and Rina Ariffin and Jafaru Abu and Caroline Chapman and Suha Deen and David Nunns and Barrett, {David A.} and Claire Seedhouse and William Atiomo",
year = "2014",
month = "1",
doi = "10.1016/j.ygyno.2013.10.028",
language = "English",
volume = "132",
pages = "248--253",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women

T2 - Could metformin help?

AU - Shafiee, Mohamad Nasir

AU - Khan, Gulafshana

AU - Ariffin, Rina

AU - Abu, Jafaru

AU - Chapman, Caroline

AU - Deen, Suha

AU - Nunns, David

AU - Barrett, David A.

AU - Seedhouse, Claire

AU - Atiomo, William

PY - 2014/1

Y1 - 2014/1

N2 - Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic.

AB - Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic.

KW - Endometrial cancer

KW - Endometrial hyperplasia

KW - Metformin

KW - PCOS

UR - http://www.scopus.com/inward/record.url?scp=84892802913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892802913&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2013.10.028

DO - 10.1016/j.ygyno.2013.10.028

M3 - Article

C2 - 24183733

AN - SCOPUS:84892802913

VL - 132

SP - 248

EP - 253

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -